An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, providing for the definitions of "clinical trial" and "pharmaceutical drug" and for drug manufacturer clinical trials reporting; and further providing for prohibited acts and penalties.